WallStSmart

Alector Inc (ALEC)vsModerna Inc (MRNA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Moderna Inc generates 15972% more annual revenue ($2.23B vs $13.86M). ALEC leads profitability with a 0.0% profit margin vs -141.4%. MRNA earns a higher WallStSmart Score of 21/100 (F).

ALEC

Avoid

17

out of 100

Grade: F

Growth: 2.0Profit: 2.5Value: 6.0Quality: 7.0
Piotroski: 4/9Altman Z: -5.30

MRNA

Avoid

21

out of 100

Grade: F

Growth: 2.7Profit: 2.0Value: 6.7Quality: 7.5
Piotroski: 3/9Altman Z: 2.09
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ALECUndervalued (+28.4%)

Margin of Safety

+28.4%

Fair Value

$2.68

Current Price

$2.14

$0.54 discount

UndervaluedFair: $2.68Overvalued
MRNAUndervalued (+70.0%)

Margin of Safety

+70.0%

Fair Value

$134.97

Current Price

$143.97

$9.00 discount

UndervaluedFair: $134.97Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ALEC1 strengths · Avg: 10.0/10
Debt/EquityHealth
-3.2910/10

Conservative balance sheet, low leverage

MRNA2 strengths · Avg: 9.0/10
Market CapQuality
$56.02B9/10

Large-cap with strong market position

Debt/EquityHealth
0.199/10

Conservative balance sheet, low leverage

Areas to Watch

ALEC4 concerns · Avg: 2.5/10
Market CapQuality
$238.95M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Return on EquityProfitability
-238.9%2/10

ROE of -238.9% — below average capital efficiency

Revenue GrowthGrowth
-57.8%2/10

Revenue declined 57.8%

MRNA4 concerns · Avg: 3.3/10
Price/BookValuation
8.5x4/10

Trading at 8.5x book value

Revenue GrowthGrowth
2.1%4/10

2.1% revenue growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-46.6%2/10

ROE of -46.6% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : ALEC

The strongest argument for ALEC centers on Debt/Equity.

Bull Case : MRNA

The strongest argument for MRNA centers on Market Cap, Debt/Equity.

Bear Case : ALEC

The primary concerns for ALEC are Market Cap, Profit Margin, Return on Equity.

Bear Case : MRNA

The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.

Key Dynamics to Monitor

ALEC profiles as a value stock while MRNA is a turnaround play — different risk/reward profiles.

MRNA carries more volatility with a beta of 1.11 — expect wider price swings.

MRNA is growing revenue faster at 2.1% — sustainability is the question.

ALEC generates stronger free cash flow (-34M), providing more financial flexibility.

Bottom Line

MRNA scores higher overall (21/100 vs 17/100). ALEC offers better value entry with a 28.4% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Alector Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Alector, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of neurodegenerative diseases. The company is headquartered in South San Francisco, California.

Moderna Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.

Want to dig deeper into these stocks?